IP Verse

Compositions And Methods For Treating Hematologic Cancers Targeting The Sirp Alpha- Cd47 Interaction - EP2995315

EP2995315

THE HOSPITAL FOR SICK CHILDREN
Application Number
EP15160169A
Filing Date
May 14, 2010
Status
Granted And Under Opposition
Nov 24, 2023
Grant Date
Dec 27, 2023
External Links
Slate, Register, Google Patents

Bibliography

The patent EP2995315B1 was granted to The Hospital FOR Sick Children on Dec 27, 2023 following the initial filing on May 14, 2010 under the application number EP15160169A . The current legal status of the patent is Granted And Under Opposition.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

LEEMINGFeb 22, 2024ADMISSIBLE

Patent Citations New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePatent NumberPatent Link
DESCRIPTIONUS5116964
DESCRIPTIONUS5580756
DESCRIPTIONUS5624821
DESCRIPTIONUS5648260
DESCRIPTIONUS5844095
DESCRIPTIONUS5869046
DESCRIPTIONUS6121022
DESCRIPTIONUS6194551
DESCRIPTIONWO2009046541
DESCRIPTIONWO2009065541
DESCRIPTIONWO9429351
OTHERWO2010130053
SEARCHWO2009046541
SEARCHWO9940940

Non-Patent Literature (NPL) Citations New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- SANO, S. ET AL., BIOCHEM J, (1999), vol. 344, pages 667 - 75-
DESCRIPTION- SHULTZ,L.D. ET AL., "Multiple defects in innate and adaptive immunologic function in NOD/LtSz-sc/ii mice", J IMMUNOI, (1995), vol. 154, pages 180 - 191-
DESCRIPTION- MAJETI,R. ET AL., "CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells", CELL, (2009), vol. 138, doi:doi:10.1016/j.cell.2009.05.045, page 286, XP055277135
DESCRIPTION- WANG, J.C.; DICK, J.E., "Cancer stem cells: lessons from leukemia", TRENDS CELL BIOL., (2005), vol. 15, doi:doi:10.1016/j.tcb.2005.07.004, pages 494 - 501, XP005058818
DESCRIPTION- MATOZAKI,T.; MURATA,Y.; OKAZAWA,H.; OHNISHI,H., "Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway", TRENDS CELL BIOL., (2009), vol. 19, doi:doi:10.1016/j.tcb.2008.12.001, pages 72 - 80, XP025913010
DESCRIPTION- TAKENAKA, K. ET AL., "Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells", NAT. IMMUNOL., (2007), vol. 8, doi:doi:10.1038/ni1527, pages 1313 - 1323, XP008133576
EXAMINATION- MAJETI RAVINDRA ET AL, "CD47 Is An Independent Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, (20081101), vol. 112, no. 11, ISSN 0006-4971, page 284, XP009160228-
EXAMINATION- M. Seiffert ET AL, "Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34+CD38- hematopoietic cells", Blood, (20010501), vol. 97, no. 9, doi:10.1182/blood.V97.9.2741, ISSN 0006-4971, pages 2741 - 2749, XP055056736
SEARCH- RAVINDRA MAJETI1 ET AL, "CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells", DEVELOPMENTAL CELL, CELL PRESS, CAMBRIDGE, MA, US, vol. 138, no. 2, doi:10.1016/J.CELL.2009.05.045, ISSN 1097-4172, (20090723), pages 286 - 299, (20090723), XP002632714 [PX] 1-15 * see whole doc. esp. Figs.5,6 *
SEARCH- MATOZAKI T ET AL, "Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway", TRENDS IN CELL BIOLOGY, ELSEVIER SCIENCE LTD, XX, vol. 19, no. 2, doi:10.1016/J.TCB.2008.12.001, ISSN 0962-8924, (20090201), pages 72 - 80, (20090112), XP025913010 [DA] 1-15 * the whole document *
SEARCH- KATSUTO TAKENAKA ET AL, "Polymorphism in Sira modulates engraftment of human hematopoietic stem cells", NATURE IMMUNOLOGY, NATURE PUBLISHING GROUP, GB, vol. 8, no. 12, doi:10.1038/NI1527, ISSN 1529-2908, (20071201), pages 1313 - 1323, (20071104), XP008133576 [A] 1-15 * the whole document *
SEARCH- IDE K ET AL, "Role for CD47-SIRP[alpha] signaling in xenograft rejection by macrophages", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 104, no. 12, doi:10.1073/PNAS.0609661104, ISSN 0027-8424, (20070320), pages 5062 - 5066, (20070312), XP002608756 [A] 1-15 * the whole document *
SEARCH- S. FLORIAN, "Evaluation of normal and neoplastic human mast cells for expression of CD172a (SIRP ), CD47, and SHP-1", JOURNAL OF LEUKOCYTE BIOLOGY, (20050309), vol. 77, no. 6, doi:10.1189/jlb.0604349, ISSN 0741-5400, pages 984 - 992, XP055036380 [X] 1-15 * see whole doc. esp. p.990, 2. col., 2.apr., *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents